FATE
Fate Therapeutics, Inc.
There isn't enough reported data to score FATE yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
FATE Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Unavailable |
FATE's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
FATE PE Valuation
FATE has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
FATE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect FATE's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
FATE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.03 | +$0.29 |
| Q2 2026 | -$1.05 | +$0.40 |
| Q1 2026 | -$1.09 | +$0.40 |
| Q4 2025 | -$1.15 | +$0.49 |
| Q3 2025 | -$1.32 | +$0.33 |
| Q2 2025 | -$1.45 | +$0.26 |
| Q1 2025 | -$1.49 | +$0.43 |
| Q4 2024 | -$1.64 | $0.00 |
FATE is still losing money, but far less than before: $1.03 per share over the past year, against $3.06 at its worst in late 2022.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over FATE on earnings quality, reporting a profit while its opponent remains loss making.
FATE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2.1M | +9.2% |
| Q1 2026 | $1.3M | -20% |
| Q4 2025 | $1.4M | -26% |
| Q3 2025 | $1.7M | -43% |
| Q2 2025 | $1.9M | -72% |
| Q1 2025 | $1.6M | -15% |
| Q4 2024 | $1.9M | +11% |
| Q3 2024 | $3.1M | +58% |
FATE's revenue has slid since its 2023 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1495% | +443 points |
| Q1 2026 | -2540% | -6.3 points |
| Q4 2025 | -2536% | +784 points |
| Q3 2025 | -1995% | -291 points |
| Q2 2025 | -1939% | -1273 points |
| Q1 2025 | -2534% | +119 points |
| Q4 2024 | -3320% | -451 points |
| Q3 2024 | -1704% | +934 points |
FATE's operating margin was −1495% last quarter, up 443 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over FATE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over FATE on profitability, with a higher operating margin.
FATE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$27.8M | -$1.2M |
| Q2 2026 | -$23.5M | +$2.5M |
| Q1 2026 | -$31.1M | +$3.9M |
| Q4 2025 | -$24.5M | +$3.4M |
| Q3 2025 | -$26.6M | +$3.3M |
| Q2 2025 | -$25.9M | +$6.4M |
| Q1 2025 | -$35M | -$1.6M |
| Q4 2024 | -$27.9M | +$8.9M |
FATE has burned cash in almost every quarter: −$107M over the past year, against −$115M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over FATE on cash generation, producing positive trailing cash flow while its opponent burns cash.
FATE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +3.3M shares |
| 1 year | +3.9% | +4.7M shares |
| 3 years | +25% | +25.1M shares |
| 5 years | +30% | +28.2M shares |
| Available history | +81% | +55.5M shares |
FATE has 124M diluted shares, up 3.9% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over FATE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
FATE Net Leverage
FATE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
FATE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 14.1 | Oversold |
FATE's weekly RSI is 38 (neutral) and its Stochastic is 14 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
FATE PE vs Healthcare Sector
FATE has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
FATE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.00 | 33% below |
| 20 week MA | $2.36 | 43% below |
| 50 week MA | $1.83 | 27% below |
| 100 week MA | $1.51 | 11% below |
| 200 week MA | $2.88 | 53% below |
FATE is in a downtrend: it's below all five of its weekly moving averages, and 53% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over FATE on trend strength, trading above more of its moving averages.
FATE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.7 | $99.5 | +404% |
| 2021 | $99.5 | $64.3 | -35% |
| 2022 | $64.3 | $11.0 | -83% |
| 2023 | $11.0 | $3.74 | -66% |
| 2024 | $3.74 | $1.61 | -57% |
| 2025 | $1.61 | $1.00 | -38% |
| 2026 YTD | $1.00 | $1.34 | +34% |
FATE has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.